Itamar Medical Ltd. (ITMR)
| Market Cap | 381.09M |
| Revenue (ttm) | 41.03M |
| Net Income (ttm) | -10.94M |
| Shares Out | 16.39M |
| EPS (ttm) | -0.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 12 |
| Last Price | $21.82 |
| Previous Close | $22.62 |
| Change ($) | -0.80 |
| Change (%) | -3.54% |
| Day's Open | 22.08 |
| Day's Range | 21.39 - 22.30 |
| Day's Volume | 10,881 |
| 52-Week Range | 12.68 - 29.00 |
Itamar Medical Ltd. Sponsored ADR (ITMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Itamar Medical's WatchPAT® Technology Featured in Ladenburg Thalmann Healthcare Symposia Call Series
CAESAREA, Israel, May 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management i...
CAESAREA, Israel, May 05, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management i...
Significant Majority Expect Home Sleep Apnea Test Usage to Expand and in-lab Usage to Decline
Itamar Medical Ltd. Sponsored ADR (ITMR) delivered earnings and revenue surprises of -7.14% and 0.57%, respectively, for the quarter ended December 2020.
Shares of Itamar Medical (NASDAQ:ITMR) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share fell 400.00% over the past year to ($0.15), which missed the estima...
- Record Fourth Quarter 2020 Revenues Increase 31% to $ 12.8 Million -
CAESAREA, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management ...
CAESAREA, Israel, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical dev...
CAESAREA, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and comme...
CAESAREA, Israel, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and comme...
CAESAREA, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, February 4th by Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), please note that the contact...
CAESAREA, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and comme...
CAESAREA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management ...
This $356 million market cap sleep apnea company is betting it can triple its market cap. If history is any guide, it will return nearly 30% a year.
CAESAREA, Israel, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management ...
CAESAREA, Israel, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management ...
Positive Coverage Policy from Health Care Service Corporation (HCSC) Covers Blue Cross Blue Shield Members in Illinois, Montana, New Mexico, Oklahoma and Texas Positive Coverage Policy from Health Care ...
WatchPAT™ to effectively maintain current reimbursement levels despite broader reduction in conversion rates WatchPAT™ to effectively maintain current reimbursement levels despite broader reduction in c...
Results Further Support Use of WatchPAT for Home-Based Sleep Apnea Testing as an Effective Alternative to In-Lab PSG Testing Results Further Support Use of WatchPAT for Home-Based Sleep Apnea Testing as...
CAESAREA, Israel, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology and digital health company focused on the development and commercialization of non-i...
Itamar Medical Ltd. (ITMR) CEO Gilad Glick on Q3 2020 Results - Earnings Call Transcript
Initial findings show potential for material short-term annual savings of up to $5,000 per cardiovascular patient when treated for sleep apnea Initial findings show potential for material short-term ann...
- Third Quarter Revenues Increase 36 % to $ 11.0 Million -
CAESAREA, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical...
CAESAREA, Israel, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the diagnosis of sleep apnea and other res...
Q3 Total Revenue Results of $10.7 M to $ 11 . 0 M , reflecting growth of 32 %- 36 %
CAESAREA, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the diagnosis of sleep apnea and other res...
Updated guidelines represent a significant milestone in the adoption of Itamar’s Peripheral Arterial Tonometry (PAT) based Home Sleep Apnea Testing (HSAT) in Europe, following adoption in the UK, Hollan...
CAESAREA, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology and digital health company focused on the development and commercialization of no...
CAESAREA, Israel, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology and digital health company focused on the development and commercialization of non...
As a platinum sponsor, Itamar Medical’s virtual booth and on-demand content to be offered to SLEEP 2020 attendees As a platinum sponsor, Itamar Medical’s virtual booth and on-demand content to be offere...
Itamar Medical Ltd. (ITMR) CEO Gilad Glick on Q2 2020 Results - Earnings Call Transcript
Itamar Medical Ltd. Sponsored ADR (ITMR) delivered earnings and revenue surprises of 10.53% and 12.18%, respectively, for the quarter ended June 2020.
Itamar Medical Ltd. Sponsored ADR (ITMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
CAESAREA, Israel, July 27, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medic...
Itamar Medical (ITMR) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Itamar Medical Ltd. Sponsored ADR (ITMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
As of late, it has definitely been a great time to be an investor in Itamar Medical.
- First Quarter 2020 Revenues Increase 38% to $8.4 Million -
Complete, home-based solution for diagnosing respiratory sleep disorders approved for commercialization in Europe and other CE Mark geographies Complete, home-based solution for diagnosing respiratory s...
Study conducted at Mount Sinai Hospital in New York City designed to demonstrate benefit of continuous positive airway pressure (CPAP) in delaying or eliminating hospitalization and/or ventilation in pa...
- Company Ramping Up WatchPAT™ ONE Production Capacity to Meet Demand for Disposable Home Sleep Apnea Tests -
Streamlining the complex process from sleep apnea diagnosis to treatment using digital health platforms meets shared mission of addressing the growing and undermanaged sleep apnea epidemic
CAESAREA, Israel, March 20, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive med...
Study will evaluate how raw signals from tens of thousands of WatchPAT recordings conducted over the last 10 years in combination with health medical records can be leveraged to predict cardiovascular o...
Two additional published studies highlight WatchPAT’s accuracy and effectiveness in patients with Central Sleep Apnea (CSA) and Chronic Obstructive Pulmonary Disease (COPD)
CAESAREA, Israel, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medic...
CAESAREA, Israel, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medic...
CAESAREA, Israel, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medic...
About ITMR
Itamar Medical Ltd., a medical technology company, develops and commercializes non-invasive medical devices and solutions for the treatment of respiratory sleep disorders. The company offers medical devices based on Peripheral Arterial Tone (PAT) signal, which measures changes in the patient's peripheral arterial pulse volumes and various parameters of arterial activities. It provides WatchPAT device, which enable to conduct home sleep apnea tests for the treatment of sleep apnea, such as obstructive sleep apnea; EndoPAT device that diagnoses e... [Read more...]
| Industry Medical Devices | Founded 1997 |
| Stock Exchange NASDAQ | Ticker Symbol ITMR |
Financial Performance
In 2020, Itamar Medical's revenue was $41.03 million, an increase of 31.28% compared to the previous year's $31.26 million. Losses were -$10.94 million, 107.6% more than in 2019.
Analyst Forecasts
According to 6 analysts, the average rating for Itamar Medical stock is "Strong Buy." The 12-month stock price forecast is 30.92, which is an increase of 41.70% from the latest price.